The Fertility Partnership has today signed an agreement to acquire VivaNeo GmbH from Waterland Private Equity. VivaNeo is one of the leading European providers of fertility services with 9 clinics supported by 5 satellite clinics across Germany, Austria, Denmark and the Netherlands. The group includes a blood diagnostics laboratory in Germany servicing the local market and some international clinics, as well as a dialysis business in Germany.
- The Fertility Partnership (“TFP”) is one of the leading European providers of fertility services, ultrasound pregnancy scans and hormone treatments with 10 fertility clinics in in the UK and Poland. TFP was acquired by Impilo in March 2019.
- VivaNeo GmbH (“VivaNeo”) is one of the leading European providers of fertility services, with 9 fertility clinics across Austria, Denmark, Netherlands and Germany employing ~300 employees.
- The combined group will deliver superior patient experience across 19 clinics in 6 counties and deliver ~24,000 cycles and 110 million EUR revenues annually
- Impilo is excited about the acquisition of VivaNeo supporting the strategy of building the pan-European fertility leader
The Fertility Partnership has today signed an agreement to acquire VivaNeo GmbH from Waterland Private Equity. VivaNeo is one of the leading European providers of fertility services with 9 clinics supported by 5 satellite clinics across Germany, Austria, Denmark and the Netherlands. The group includes a blood diagnostics laboratory in Germany servicing the local market and some international clinics, as well as a dialysis business in Germany.
In 2011, the first VivaNeo clinic was acquired in Wiesbaden. Between 2011 and 2014, the group expanded in Germany and the Netherlands with clinics added in Berlin, Dusseldorf and Leiderdorp. From 2015 to 2019 the group rapidly expanded acquiring 3 clinics in Austria and 2 in Denmark. Since inception, the group’s focus has been on the provision of best-in-class patient experience supported by scientific and clinical excellence. VivaNeo now delivers ~14,000 cycles annually, with revenues of approximately €50m million and ~300 full-time employees.
“We are excited and delighted to welcome the VivaNeo team to The Fertility Partnership family. There is a strong cultural compatibility between the groups both being absolutely focused focus on providing best in class fertility treatments and patient care during the IVF journey. Together, through an expansive network of like-minded professionals, we will be able to further improve patient experience and success rates through broader investment in research and technology.” says Andrew Came, CEO of TFP.
The Impilo team is excited about the investment: “Through this investment we are a step closer to our vision of creating the pan-European leader in the provision of fertility services. We are highly impressed with VivaNeo’s excellent clinical and scientific standing in the community alongside their unwavering commitment to superior patient experience. We are looking forward to actively supporting the growth and development of the combined group and more broadly contributing to the development of the fertility industry.” – says Hans-Christian Bødker Jensen, responsible Partner at Impilo.
About The Fertility Partnership
The Fertility Partnership is a leading European provider of fertility services, ultrasound pregnancy scans and hormone treatments present in the UK and in Poland. The group comprises 8 IVF clinics in the UK, 2 IVF clinics in Poland, 88 ultrasound clinics in the UK, as well as a nascent hormone treatment business. TFP was founded in 2012 through the merger of two IVF clinics and has since expanded through further add-on acquisitions, greenfield developments and expansion into adjacent services. Today it is the largest provider of fertility services in the UK and the third largest in Poland; it also operates the UK’s leading independent provider of ultrasound scanning services. Learn more about TFP at https://www.thefertilitypartnership.com/
About Viva Neo
Viva Neo is a leading European provider of fertility services, present in Germany, Austria, the Netherlands and Denmark. The group comprises 9 IVF clinics across four countries, an egg donor bank, as well as a blood diagnostic laboratory and a dialysis centre in Germany. It holds the number 1 or 2 market position in market share terms in each of its markets. The group focus is on best-in-class patient experience and success rates.
Learn more about Viva Neo at https://vivaneo-ivf.com/en/
About Impilo
Impilo is a Nordic-based investment company focused on investments in healthcare companies active in pharmaceuticals, medical technology, healthcare services and other health-related areas. Impilo’s perspective is that the portfolio companies must contribute to a positive development in their fields and thus society in order to be successful long term. Impilo manages over SEK 3.5 billion in capital from leading Nordic and international investors. Larger investors include AP3 (The Third Swedish National Pension Fund), Tryghedsgruppen and Goldman Sachs Asset Management. Learn more about Impilo at www.impilo.se.
For further information, please contact: Andrew Came, CEO, The Fertility Partnership, +44 7912 120675, a.came@thefertilitypartnership.com
Hans-Christian Bødker Jensen, Partner, Impilo AB, +45 22 70 20 21, hc.bodker@impilo.se
News
KKR and Impilo announce strategic partnership together with management in rare disease platform Immedica Pharma
Stockholm and London, 23 April 2024 – Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Nordic healthcare investment firm Impilo, will reinvest to become an equal owner alongside KKR. The transaction is subject to customary regulatory and closing conditions.
Impilo invests in Avia Pharma – a leading OTC and Rx pharmaceutical platform
Impilo has closed its investment in Avia Pharma Holding AB, a Sweden-based OTC and Rx pharmaceutical company with presence in the Nordics and Germany. Impilo now partners with two of the co-founders and management of Avia. Our ambition is to build a leading Northern European OTC / Rx platform through organic and inorganic growth.
Loargys® (pegzilarginase) approved in the EU for treatment of arginase 1 deficiency (ARG1-D)
Immedica today announces that the European Commission has granted marketing authorization of Loargys® (pegzilarginase) for the treatment of arginase 1 deficiency (ARG1-D), also known as hyperargininemia, in adults, adolescents and children aged 2 years and older. The approval follows the positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use on October 12.